NEW YORK–(BUSINESS WIRE)–Oct. 21, 2003–Callisto Pharmaceuticals, Inc. (OTCBB: CLSP – News) announced that Dr. Moshe Talpaz, Chairman of the Department of Bioimmunotherapy of The University of Texas M. D. Anderson Cancer Center has become a member of Callisto’s Scientific Advisory Board. Dr. Talpaz, well known for his role in the clinical development of Gleevec, is…
New York, New York – October 7, 2003 – Callisto Pharmaceuticals, Inc. (OTCBB: CLSP – News) announced that it has received a $265,000 Small Business Technology Transfer Research grant from the National Institutes of Health for studies on Atiprimod, Callisto’s lead drug candidate for multiple myeloma. The Principal and Co-Principal Investigators of the grant entitled…
New York, New York – September 24, 2003 – Callisto Pharmaceuticals, Inc. (OTCBB: CLSP) today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its cancer drug Atiprimod. The planned Phase I/IIa clinical trial is an open label study of the safety and efficacy of…